Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Closing the paediatric gap in cancer drug development: a call to industry.

Nature reviews. Drug discovery·2026
Same author

Should We Call Every Cancer a Rare Cancer?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Knowledge Is Power.

Targeted oncology·2026
Same author

Biomarker study of pembrolizumab in patients with advanced rare cancers.

Cell reports. Medicine·2026
Same author

Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.

Cancer immunology, immunotherapy : CII·2026
Same journal

Correction: Epidemiology and Real-World Outcomes in Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Mutant Non-small Cell Lung Cancer by Region: A Targeted Literature Review.

Targeted oncology·2026
Same journal

Efficacy and Safety Differences Between Abiraterone and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-analysis of Real-World Studies.

Targeted oncology·2026
Same journal

Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma.

Targeted oncology·2026
Same journal

Afatinib Versus Osimertinib as First-Line Treatment for Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A 3-Year Follow-Up Overall Survival Analysis.

Targeted oncology·2026
Same journal

Real-World Outcomes of Adjuvant Pembrolizumab for Renal Cell Carcinoma: The Potential Role of PD-L1 as a Prognostic Biomarker.

Targeted oncology·2026
Same journal

Should Metastatic Site Inform First-Line Therapy in Clear Cell Renal Cell Carcinoma?

Targeted oncology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients.

Vivek Subbiah1, Martin Dietrich2

  • 1Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. viveksubbiah@outlook.com.

Targeted Oncology
|May 13, 2026
PubMed
Summary
This summary is machine-generated.

Accurate HER2 mutation testing is crucial for non-small cell lung cancer (NSCLC) patients. Early molecular diagnosis ensures personalized therapy, improving outcomes in HER2-mutant NSCLC.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: May 14, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • HER2 mutations are a targetable driver in a subset of non-small cell lung cancer (NSCLC).
  • Identifying these mutations is critical for guiding personalized treatment strategies.
  • Current diagnostic approaches face challenges in timely and comprehensive HER2 mutation detection.

Purpose of the Study:

  • To highlight the importance of early and accurate HER2 mutation testing in NSCLC.
  • To discuss the integration of next-generation sequencing (NGS) and molecular profiling in clinical practice.
  • To address practical challenges and evolving standards in HER2 mutation diagnostics.

Main Methods:

  • Discussion of next-generation sequencing (NGS) and comprehensive molecular profiling.
  • Exploration of tumor biopsies and liquid biopsies for HER2 mutation detection.
  • Review of clinical practice integration and evolving diagnostic standards.

Main Results:

  • Timely and comprehensive HER2 testing is vital for optimizing patient outcomes.
  • Real-world barriers like cost, access, and awareness hinder effective testing.
  • Solutions like reflex testing and pathologist collaboration can overcome diagnostic hurdles.

Conclusions:

  • Accurate and early molecular diagnosis is essential for effective, personalized therapy in HER2-mutant NSCLC.
  • The treatment landscape for HER2-mutant NSCLC is rapidly advancing, necessitating improved diagnostic capabilities.
  • Addressing diagnostic challenges is key to ensuring patients receive optimal care.